Antithrombotic Therapy for VTE Disease

ACCP VTE Therapy

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/86135

Contents of this Issue

Navigation

Page 13 of 17

Treatment ÎIn patients who have UEDVT that is associated with a central venous catheter that is removed, the ACCP recommends 3 months of anticoagulation over a longer duration of therapy in patients with no cancer (1-B), and the ACCP suggests this in patients with cancer (2-C). ÎIn patients who have UEDVT that is associated with a central venous catheter that is not removed, the ACCP recommends that anticoagulation is continued as long as the central venous catheter remains over stopping after 3 months of treatment in patients with cancer (1-C), and the ACCP suggests this in patients with no cancer (2-C). ÎIn patients who have UEDVT that is not associated with a central venous catheter or with cancer, the ACCP recommends 3 months of anticoagulation over a longer duration of therapy (1-B). ÎIn patients with acute symptomatic UEDVT, the ACCP suggests compression sleeves or venoactive medications NOT be used (2-C). 12

Articles in this issue

Archives of this issue

view archives of Antithrombotic Therapy for VTE Disease - ACCP VTE Therapy